{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:25Z","timestamp":1787008585669,"version":"build-2736575974"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Institute for Health and Biomedical Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinicians are increasingly prescribing immune checkpoint inhibitors (ICIs) to treat cancer, but the real-world incidence, characteristics and risk factors of cutaneous immune-related adverse events (cirAEs) are unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the incidence, features and risk factors of cirAEs and to measure their possible association with extracutaneous toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective observational study in a Spanish tertiary care hospital, including people who started an ICI between March 2020 and May 2022. We used a survival analysis and a log-rank test to obtain and compare incidence rates, and a multivariate Cox model to detect risk factors for cirAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 189 patients, 82 (43.4%) of whom presented cutaneous toxicity. The incidence of cirAEs was 75.0 per 100 person-years, with a 50.0% probability of the appearance of a cirAE at 10 months of follow-up. The most frequent cirAE category was inflammatory dermatoses, and the most frequent types were pruritus, eczema and maculopapular eruptions. ICI combination therapy, a family history of psoriasis and rheumatological and pulmonary immune-related adverse events increased the risk of cirAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found a high incidence of cirAEs, and they occurred early in the follow-up period. Dermatologists should be involved in the management of cirAEs, especially in people with risk factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llae060","type":"journal-article","created":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T16:32:37Z","timestamp":1708187557000},"page":"991-1001","source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity \u2013 a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital"],"prefix":"10.1093","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-5328","authenticated-orcid":false,"given":"Gloria","family":"Juan-Carpena","sequence":"first","affiliation":[{"name":"Department of Dermatology, Morales Meseguer University Hospital , Murcia , Spain"},{"name":"Toxirel Investigation Group , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Mart\u00ednez-Banaclocha","sequence":"additional","affiliation":[{"name":"Toxirel Investigation Group , Alicante , Spain"},{"name":"Department of Oncology, Dr. Balmis University General Hospital , Alicante , Spain"},{"name":"Institute for Health and Biomedical Research (ISABIAL) , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Palaz\u00f3n-Cabanes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, 12 de Octubre University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Niveiro-de Jaime","sequence":"additional","affiliation":[{"name":"Institute for Health and Biomedical Research (ISABIAL) , Alicante , Spain"},{"name":"Department of Pathology, Dr. Balmis University General Hospital , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Betlloch-Mas","sequence":"additional","affiliation":[{"name":"Institute for Health and Biomedical Research (ISABIAL) , Alicante , Spain"},{"name":"Dermatology, Dr. Balmis University General Hospital , Alicante , Spain"},{"name":"Miguel Hern\u00e1ndez University of Elche , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Blanes-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Toxirel Investigation Group , Alicante , Spain"},{"name":"Institute for Health and Biomedical Research (ISABIAL) , Alicante , Spain"},{"name":"Dermatology, Dr. Balmis University General Hospital , Alicante , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"2024082301140477600_llae060-B1","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024082301140477600_llae060-B2","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"2024082301140477600_llae060-B3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2024082301140477600_llae060-B4","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B5","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2024082301140477600_llae060-B6","doi-asserted-by":"crossref","first-page":"570752","DOI":"10.3389\/fonc.2020.570752","article-title":"Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors","volume":"10","author":"Rose","year":"2021","journal-title":"Front Oncol"},{"key":"2024082301140477600_llae060-B7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"2024082301140477600_llae060-B8","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol"},{"key":"2024082301140477600_llae060-B9","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2024082301140477600_llae060-B10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024082301140477600_llae060-B11","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-\u00adrelated adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024082301140477600_llae060-B12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdv.17855","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force \u2018Dermatology for cancer patients\u2019 position statement","volume":"36","author":"Apalla","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024082301140477600_llae060-B13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ad.2021.09.005","article-title":"Characteristics, management, and prognostic implications of adverse effects of immune checkpoint inhibitors: a systematic review","volume":"113","author":"Juan-Carpena","year":"2022","journal-title":"Actas Dermosifilogr"},{"key":"2024082301140477600_llae060-B14","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.3390\/curroncol29040234","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: a review article","volume":"29","author":"Chen","year":"2022","journal-title":"Curr Oncol"},{"key":"2024082301140477600_llae060-B15","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2023.0208","article-title":"Interleukin-17 monoclonal antibody successfully treated psoriasiform drug eruption induced by immune checkpoint inhibitors: a report and review of literature","author":"Li","year":"2023","journal-title":"Dermatitis"},{"key":"2024082301140477600_llae060-B16","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2024082301140477600_llae060-B17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J\u00a0Cutan Pathol"},{"key":"2024082301140477600_llae060-B18","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024082301140477600_llae060-B19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"key":"2024082301140477600_llae060-B20","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.critrevonc.2020.102983","article-title":"Patients with lung cancer undergoing immune checkpoint inhibitors: a meta-analysis of dermatological toxicities","volume":"152","author":"Garrett","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024082301140477600_llae060-B21","doi-asserted-by":"crossref","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of us patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2024082301140477600_llae060-B22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B24","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B26","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2024082301140477600_llae060-B28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024082301140477600_llae060-B30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B31","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024082301140477600_llae060-B32","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"2024082301140477600_llae060-B33","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"2024082301140477600_llae060-B34","doi-asserted-by":"crossref","first-page":"103376","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: a systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024082301140477600_llae060-B35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CMR.0000000000000518","article-title":"Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma","volume":"29","author":"Hwang","year":"2019","journal-title":"Melanoma Res"},{"key":"2024082301140477600_llae060-B36","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B37","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: a predictor of tumour response under anti-PD-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024082301140477600_llae060-B38","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024082301140477600_llae060-B39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","article-title":"Cutaneous adverse reactions to anti-PD-1 treatment \u2013 a systematic review","volume":"83","author":"Simonsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B40","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2024082301140477600_llae060-B41","doi-asserted-by":"crossref","first-page":"965550","DOI":"10.3389\/fimmu.2022.965550","article-title":"Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: an ambispective cohort study","volume":"13","author":"Luangnara","year":"2022","journal-title":"Front Immunol"},{"key":"2024082301140477600_llae060-B42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br J Dermatol"},{"key":"2024082301140477600_llae060-B43","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B45","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024082301140477600_llae060-B46","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: a multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024082301140477600_llae060-B48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2024082301140477600_llae060-B49","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti-\u00adprogrammed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301140477600_llae060-B50","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open"},{"key":"2024082301140477600_llae060-B51","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"2024082301140477600_llae060-B52","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1530\/EJE-20-1362","article-title":"Metabolic disease and adverse events from immune checkpoint inhibitors","volume":"184","author":"Leiter","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2024082301140477600_llae060-B53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2020.01.011","article-title":"Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: implications for patients being treated with checkpoint inhibitors for cancer","volume":"97","author":"Yu","year":"2020","journal-title":"J Dermatol Sci"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae060\/57390534\/llae060.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/9\/991\/58893133\/llae060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/9\/991\/58893133\/llae060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:24:03Z","timestamp":1724372643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/9\/991\/7610215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,2,19]]},"published-print":{"date-parts":[[2024,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae060","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,2,19]]}}}